Retatrutide Dosing and Tracking: What Early Users Should Know
Matt · May 14, 2026
Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon) being studied for weight loss and metabolic health. In published trials it's typically given as a weekly subcutaneous injection, starting around 0.5–2 mg and titrating up over months. It's not FDA-approved, so anyone using it outside a trial is doing so in a research context and should be working with a qualified clinician.
Why Retatrutide Is Different From Semaglutide and Tirzepatide
Semaglutide (Wegovy, Ozempic) hits a single receptor: GLP-1. Tirzepatide (Mounjaro, Zepbound) hits two: GLP-1 and GIP. Retatrutide adds a third — glucagon — which is thought to increase energy expenditure on top of appetite suppression. In Phase 2 trials, participants on higher doses saw average weight reductions north of 20% at 48 weeks, which is why the peptide community has been paying close attention.
That said, more receptors usually means more variables. Heart rate, blood pressure, and GI symptoms have all shown up in early data, which makes consistent tracking even more important than with single-agonist drugs.
A Typical Titration Pattern From Published Trials
Trial protocols generally followed a slow ramp to reduce nausea and GI issues. A common pattern:
- Weeks 1–4: 0.5 mg weekly
- Weeks 5–8: 2 mg weekly
- Weeks 9–12: 4 mg weekly
- Weeks 13+: Step up to 8 mg or 12 mg depending on tolerance and study arm
This is what researchers used — it's not a recommendation. Real-world protocols vary, and many users report needing slower escalation to manage side effects. Talk to your doctor before adjusting anything.
What to Track Week by Week
Because retatrutide affects multiple systems, a single weight check isn't enough to see the whole picture. Things worth logging:
- Dose, date, and injection site — rotating sites matters with weekly injections
- Weight and waist measurement — weekly, same time of day
- Resting heart rate — trials have shown small but consistent increases
- GI side effects — nausea, reflux, constipation, severity 1–10
- Energy and sleep quality — the glucagon arm may shift both
- Hunger and food noise — the main subjective signal of dose adequacy
- Lab markers — fasting glucose, A1C, lipids, liver enzymes every 8–12 weeks if your clinician agrees
A private logbook like Trace makes this easier — you can log doses, sites, symptoms, and labs in one place, and everything stays on your device behind Face ID. For something this new, that privacy piece matters to a lot of users.
Frequently Asked Questions
Is retatrutide FDA-approved?
No. As of 2026 it's still in Phase 3 trials. Eli Lilly has indicated they're working toward an approval submission, but any use outside a clinical trial is off-label research use.
How does retatrutide compare to tirzepatide for weight loss?
Head-to-head data is limited, but Phase 2 results suggest higher average weight loss on retatrutide at peak doses. Side effect rates also appeared higher, so the practical answer depends on tolerance and goals. Your doctor is the right person to discuss this with.
Do I need to track heart rate on retatrutide?
Many users do, since trials reported modest heart rate increases. A weekly resting check (or daily if you wear an Apple Watch) gives you a trend line worth showing your clinician if anything shifts.